TOCA - トカジェン （Tocagen Inc.） トカジェンTOCAのチャート
TOCAの企業情報
| symbol | TOCA |
|---|---|
| 会社名 | Tocagen Inc （トカジェン） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 トカジェン(Tocagen Inc.)は臨床段階のがん選択的遺伝子治療会社である。同社はがんに対する患者の免疫システムを活性化するように設計された製品候補の開発に従事する。がん選択的遺伝子治療プラットフォームは治療遺伝子をがん細胞のデオキシリボ核酸（DNA）に選択的送達するように設計されたレトロウイルス複製ベクター（RRV）上に構築される。主要製品候補はボシマジン・アミレトロレプベク（Toca 511）及びフルシトシン持続リリース(Toca FC）である。Toca 511はプロドラッグ・アクチベーター酵素、シトシンデアミナーゼ（CD）をエンコードする研究用注射用レトロウイルス複製ベクター（RRV）である。Toca FCは抗癌剤として不活性プロドラッグである5-フルオロシトシン（5-FC）の研究用持続リリースである。 トカジェンは米国のバイオ医薬品企業。臨床ステ―ジで、がん細胞に対する免疫療法の開発に従事する。ハイグレ―ド神経膠腫の治療向け「Toca 511」、また直腸がん、膵臓がん、乳がん、肺がん、皮膚がん、腎臓がんに対する療法を開発する。治療効果のある遺伝子をがん細胞に導入するレトロウィルスベクタ―も手掛ける。本社はカリフォルニア州サンディエゴ。 Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA. |
| 本社所在地 | 3030 Bunker Hill Street Suite 230 San Diego CA 92109 USA |
| 代表者氏名 | Faheem Hasnain Faheem Hasnain |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 858-412-8400 |
| 設立年月日 | 39295 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | － |
| url | www.tocagen.com |
| nasdaq_url | https://www.nasdaq.com/symbol/toca |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -48.21000 |
| 終値（lastsale） | 12.72 |
| 時価総額（marketcap） | 253778729.76 |
| 時価総額 | 時価総額（百万ドル） 253.37970 |
| 売上高 | 売上高（百万ドル） 0.03800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 199.83170 |
| 当期純利益 | 当期純利益（百万ドル） -49.75900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Tocagen Inc revenues decreased 14% to $18K. Net loss increased 60% to $29M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 75% to $23.2M (expense) General and administrative increase of 26% to $5M (expense) Interest expense increase of 30% to $1.4M (expense). |
TOCAのテクニカル分析
TOCAのニュース
Tocagen Reports First Quarter 2020 Financial Results 2020/04/23 20:05:00 PR Newswire
SAN DIEGO, April 23, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), historically a clinical-stage, cancer-selective gene therapy company, today reported financial results for the first quarter ended March 31, 2020. On February 19, 2020, Tocagen announced it had entered into a…
Tocagen Reports Fourth Quarter and Full Year 2019 Financial Results 2020/02/27 21:10:00 PR Newswire
SAN DIEGO, Feb. 27, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2019. "Following our extensive review of…
Tocagen and Forte Biosciences Announce Merger 2020/02/20 01:13:00 PR Newswire
SAN DIEGO and TORRANCE, Calif., Feb. 19, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced today that they…
HC Wainwright Reaffirms “Hold” Rating for Tocagen (NASDAQ:TOCA) 2019/11/14 15:14:27 Modern Readers
Tocagen (NASDAQ:TOCA)‘s stock had its “hold” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Thursday, AnalystRatings.com reports. A number of other equities research analysts also recently weighed in on TOCA. Chardan Capital reissued a “hold” rating and set a $1.00 price target on shares of Tocagen in […]
Tocagen Reports Third Quarter 2019 Financial Results and Business Updates 2019/11/12 21:30:00 PR Newswire
SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the third quarter ended September 30, 2019. "Following the topline readout of our Phase 3 Toca 5…
Tocagen Reports First Quarter 2020 Financial Results 2020/04/23 20:05:00 PR Newswire
SAN DIEGO, April 23, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), historically a clinical-stage, cancer-selective gene therapy company, today reported financial results for the first quarter ended March 31, 2020. On February 19, 2020, Tocagen announced it had entered into a…
Tocagen Reports Fourth Quarter and Full Year 2019 Financial Results 2020/02/27 21:10:00 PR Newswire
SAN DIEGO, Feb. 27, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2019. "Following our extensive review of…
Tocagen and Forte Biosciences Announce Merger 2020/02/20 01:13:00 PR Newswire
SAN DIEGO and TORRANCE, Calif., Feb. 19, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced today that they…
HC Wainwright Reaffirms “Hold” Rating for Tocagen (NASDAQ:TOCA) 2019/11/14 15:14:27 Modern Readers
Tocagen (NASDAQ:TOCA)‘s stock had its “hold” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Thursday, AnalystRatings.com reports. A number of other equities research analysts also recently weighed in on TOCA. Chardan Capital reissued a “hold” rating and set a $1.00 price target on shares of Tocagen in […]
Tocagen Reports Third Quarter 2019 Financial Results and Business Updates 2019/11/12 21:30:00 PR Newswire
SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the third quarter ended September 30, 2019. "Following the topline readout of our Phase 3 Toca 5…